Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129

Yushchuk O, Vior NM, Andreo-Vidal A, Berini F, Rückert C, Busche T, Binda E, Kalinowski J, Truman AW, Marinelli F (2021)
ACS chemical biology.

Zeitschriftenaufsatz | E-Veröff. vor dem Druck | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Yushchuk, Oleksandr; Vior, Natalia M; Andreo-Vidal, Andres; Berini, Francesca; Rückert, ChristianUniBi ; Busche, TobiasUniBi; Binda, Elisa; Kalinowski, JörnUniBi; Truman, Andrew W; Marinelli, Flavia
Abstract / Bemerkung
Glycopeptide antibiotics (GPAs) are last defense line drugs against multidrug-resistant Gram-positive pathogens. Natural GPAs teicoplanin and vancomycin, as well as semisynthetic oritavancin, telavancin, and dalbavancin, are currently approved for clinical use. Although these antibiotics remain efficient, emergence of novel GPA-resistant pathogens is a question of time. Therefore, it is important to investigate the natural variety of GPAs coming from so-called "rare" actinobacteria. Herein we describe a novel GPA producer-Nonomuraea coxensis DSM 45129. Its de novo sequenced and completely assembled genome harbors a biosynthetic gene cluster (BGC) similar to the dbv BGC of A40926, the natural precursor to dalbavancin. The strain produces a novel GPA, which we propose is an A40926 analogue lacking the carboxyl group on the N-acylglucosamine moiety. This structural difference correlates with the absence of dbv29-coding for an enzyme responsible for the oxidation of the N-acylglucosamine moiety. Introduction of dbv29 into N. coxensis led to A40926 production in this strain. Finally, we successfully applied dbv3 and dbv4 heterologous transcriptional regulators to trigger and improve A50926 production in N. coxensis, making them prospective tools for screening other Nonomuraea spp. for GPA production. Our work highlights genus Nonomuraea as a still untapped source of novel GPAs.
Erscheinungsjahr
2021
Zeitschriftentitel
ACS chemical biology
eISSN
1554-8937
Page URI
https://pub.uni-bielefeld.de/record/2954380

Zitieren

Yushchuk O, Vior NM, Andreo-Vidal A, et al. Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129. ACS chemical biology. 2021.
Yushchuk, O., Vior, N. M., Andreo-Vidal, A., Berini, F., Rückert, C., Busche, T., Binda, E., et al. (2021). Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129. ACS chemical biology. https://doi.org/10.1021/acschembio.1c00170
Yushchuk, O., Vior, N. M., Andreo-Vidal, A., Berini, F., Rückert, C., Busche, T., Binda, E., Kalinowski, J., Truman, A. W., and Marinelli, F. (2021). Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129. ACS chemical biology.
Yushchuk, O., et al., 2021. Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129. ACS chemical biology.
O. Yushchuk, et al., “Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129”, ACS chemical biology, 2021.
Yushchuk, O., Vior, N.M., Andreo-Vidal, A., Berini, F., Rückert, C., Busche, T., Binda, E., Kalinowski, J., Truman, A.W., Marinelli, F.: Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129. ACS chemical biology. (2021).
Yushchuk, Oleksandr, Vior, Natalia M, Andreo-Vidal, Andres, Berini, Francesca, Rückert, Christian, Busche, Tobias, Binda, Elisa, Kalinowski, Jörn, Truman, Andrew W, and Marinelli, Flavia. “Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by Nonomuraea coxensis DSM 45129”. ACS chemical biology (2021).

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 33913701
PubMed | Europe PMC

Suchen in

Google Scholar